KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.

Shin-Ichi Konno, Takuya Nikaido, John D Markman, Makoto Ohta, Toshiya Machida, Naoki Isogawa, Hiroki Yoshimatsu, Lars Viktrup, Mark T Brown, Christine R West, Kenneth M Verburg

Pain Manag 12(3) 323-335

PMID34786956
PMCID-
DOI10.2217/pmt-2021-0040
发表日期2021-11-17
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Aim & methods: This trial investigated long-term (56-week treatment/24-week follow-up) use of subcutaneous tanezumab (5 or 10 mg every 8 weeks) or oral celecoxib (200 mg/day) in Japanese patients with chronic low back pain. Results & conclusion: Tanezumab safety was consistent with previous studies, except overall adverse events (tanezumab 5 mg = 63.0%, tanezumab 10 mg = 54.8%, celecoxib = 67.4%) and events of abnormal peripheral sensation (tanezumab 5 mg = 9.8%, tanezumab 10 mg = 4.3%, celecoxib = 4.3%) were more frequent with 5 mg than 10 mg tanezumab. Joint safety event rates were 1.1% for tanezumab 5 mg, 2.2% for tanezumab 10 mg and 0% for celecoxib. All treatments improved pain and function throughout the treatment period. Clinical trial registration number: NCT02725411.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。